Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-06-28
2011-06-28
Goddard, Laura B (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S130100
Reexamination Certificate
active
07968685
ABSTRACT:
Specific binding members against extracellular matrix protein tenascin-C, especially scFv antibody molecules against domain A1, domain C and domain D of tenascin-C. Anti-tenascin-C specific binding members conjugated with labels, cytotoxic molecules or cytokines. Use of anti-tenascin-C specific binding members in diagnosis and treatment, especially of cancer.
REFERENCES:
patent: WO 00/63699 (2000-10-01), None
patent: WO 01/62800 (2001-08-01), None
Rudikoff et al. Proc Natl Acad Sci USA 1982 vol. 79 p. 1979.
MacCallum et al. J. Mol. Biol. (1996) 262, 732-745.
Pascalis et al. The Journal of Immunology (2002) 169, 3076-3084.
Casset et al. BBRC 2003, 307:198-205.
Vajdos et al. J. Mol. Biol. (2002) 320, 415-428.
Chen et al. J. Mol. Bio. (1999) 293, 865-881.
Wu et al. J. Mol. Biol. (1999) 294, 151-162.
Padlan et al. PNAS 1989, 86:5938-5942.
Lamminmaki et al. JBC 2001, 276:36687-36694.
Occhino et al. (Int. J. Mol. Med., vol. 14(3), pp. 383-388, Sep. 14, 2004) Abstract only.
B. Carnemolla et al., “Identification of a Glioblastoma-Associated Tenascin-C Isoform by a High Affinity Recombinant Antibody”, American Journal of Pathology, 154: 1345-1352 (1999).
A. Merlo et al., “Biodistribution of 111In-Labelled SCN-bz-DTPA-BC-2 Mab Following Loco-Regional Injection into Glioblastomas”, Int. J. Cancer, 71: 810-816 (1997).
M. Latinjnhouwers et al., “Expression of tenascin-C splice variants by human skin cells”, Arch. Dermatol. Res., 292: 446-454 (2000).
C.G. Davis et al., “Transgenic mice as a source of fully human antibodies for the treatment of cancer”, Cancer and Metastasis Reviews, 18: 421-425 (1999).
H.R. Hoogenboom, “Overview of Antibody Phase-Display Technology and Its Applications”, Methods in Molecular Biology, 178: 1-37 (2002).
A. Desiderio et al., “A Semi-synthetic Repertoire of Intrinsically Stable Antibody Fragments Derived from a Single-framework Scaffold”, J. Mol. Biol. 310: 603-615 (2001).
M. Silacci et al., “Design, construction, and characterization of a large synthetic human antibody phage display library”, Proteomics, 5: 2340-2350 (2005).
A. Pini et al., “Design and Use of a Phage Display Library”, The Journal of Biological Chemistry, 273: 21769-21776 (1998).
Balza, E., et al. “Production and characterization of monoclonal antibodies specific for different epitopes of human tenascin.” FEBS Lett. Oct. 11, 1993;332(1-2):39-43.
Murphy-Ullrich, J.E., et al. “Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin.” J Cell Biol. Nov. 1991;115(4):1127-36.
Hauck, M.L., et al. “The effects of clinically relevant hyperthermic temperatures on the kinetic binding parameters of a monoclonal antibody.” Nucl Med Biol. May 1996;23(4):551-7.
Reardon, D.A., et al. “Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.” J Clin Oncol. Mar. 1, 2002;20(5):1389-97.
Brack Simon
Neri Dario
Silacci Michela
Dann Dorfman Herrell & Skillman
Goddard Laura B
Hagan Patrick J.
Natarajan Meera
Philogen S.p.A.
LandOfFree
Antibodies against Tenascin-C does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies against Tenascin-C, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies against Tenascin-C will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2707381